V. Nohria

发表

EKG abnormalities in pediatric patients with myotonic dystrophy.

J. Morgenlander, V. Nohria, Z. Saba, 1993, Pediatric neurology.

A study of drug action on normal and denervated striatal mechanisms.

B. Costall, R. Naylor, V. Nohria, 1979, European journal of pharmacology.

Changes in dopamine‐dependent motor behaviour caused by propranolol and its isomers

B. Costall, R. Naylor, R. Owen, 1978, The Journal of pharmacy and pharmacology.

Hyperactivity response to apomorphine and amphetamine in the mouse: the importance of the nucleus accumbens and caudate‐putamen

R. Naylor, V. Nohria, Brenda Costaix, 1979, The Journal of pharmacy and pharmacology.

Destiny’s child Susan Anderson, and Thaddeus Kelly

M. Harrison, D. Leszczyszyn, V. Nohria, 2008 .

A review of the efficacy of the dopamine agonists pergolide and bromocriptine in the treatment of Parkinson's disease

A. Partiot, V. Nohria, 1997 .

Use of the intracerebral injection technique to elucidate mechanisms of apomorphine climbing and its antagonism in the mouse

B. Costall, R. Naylor, V. Nohria, 2004, Psychopharmacology.

Chiari I malformation: a review of 43 patients.

W. J. Oakes, V. Nohria, W. Oakes, 1990, Pediatric neurosurgery.

Lethal congenital erythroderma: a newly recognised genetic disorder

W. Reardon, J. Shield, J. Harper, 1992, Clinical genetics.

Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity.

B. Costall, R. Naylor, V. Nohria, 1978, European journal of pharmacology.

5,7-Dihydroxy-2-aminotetralin derivatives: synthesis and assessment of dopaminergic and adrenergic actions.

J. P. Long, B. Costall, R. Naylor, 1981, Journal of medicinal chemistry.

Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies

J. Pichler, U. Bogdahn, G. Schuierer, 2007 .

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.

J. Pichler, U. Bogdahn, G. Schuierer, 2007, Oligonucleotides.

A splice junction mutation in a new myopathic variant of phosphoglycerate kinase deficiency (PGK North Carolina)

S. Dimauro, S. Tsujino, P. Tonin, 1994, Annals of neurology.

Ganaxolone

E. Giller, V. Nohria, 2011, Neurotherapeutics.

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy

C. Elger, M. Brodie, H. Lerche, 2010, Neurology.

Chiari headaches

V. Nohria, W. Oakes, 1993, Neurology.

The Chédiak-Higashi syndrome: CT and MR findings

R. Tien, V. Juel, V. Nohria, 2005, Pediatric Radiology.

Magnetic Resonance Imaging Evidence of Hippocampal Sclerosis in Progression: A Case Report

T. Resnick, R. Tien, E. Heinz, 1994, Epilepsia.

Torticollis acquired in late infancy due to a cerebellar gangliocytoma.

R. Boustany, J. Caress, V. Nohria, 1996, International journal of pediatric otorhinolaryngology.

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy

R. Leroy, J. French, B. Abou-Khalil, 2011, Neurology.

Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures

W. Alves, A. Partiot, R. Sachdeo, 2007, Neurology.

Erythromycin-induced carbamazepine toxicity: a continuing problem.

C. Stafstrom, G. Delong, R. Boustany, 1995, Archives of pediatrics & adolescent medicine.

A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development.

A. Partiot, W. Rosenfeld, V. Biton, 2014, International journal of clinical pharmacology and therapeutics.

(−)N-(Chloroethyl)norapomorphine inhibits striatal dopamine function via irreversible receptor binding

B. Costall, R. Naylor, J. Neumeyer, 1980, Nature.

On the ability of N‐chloroethyl aporphine derivatives to cause irreversible inhibition of dopamine receptor mechanisms

B. Costall, R. Naylor, J. Neumeyer, 1980, The Journal of pharmacy and pharmacology.

DIFFERENTIAL EFFECT OF BENSERAZIDE (Ro4‐4602) ON THE CONCENTRATION OF INDOLEAMINES IN RAT PINEAL AND HYPOTHALAMUS

J. Arendt, A. Ho, A. Symons, 1981, British journal of pharmacology.

The mesolimbic system, denervation and the climbing response in the mouse.

B. Costall, R. Naylor, V. Nohria, 1980, European journal of pharmacology.

Synthesis and dopaminergic properties of some exo- and endo-2-aminobenzonorbornenes designed as rigid analogue of dopamine.

B. Costall, P. Crooks, R. Naylor, 1982, Journal of medicinal chemistry.

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine — a123 IBZM single photon emission tomography (SPET) study

T. Sigmundsson, T. Sharma, G. Busatto, 1996, Psychopharmacology.

Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures

M. Brodie, V. Biton, A. Gil-Nagel, 2013, Epilepsy Research.

Clinical development of drugs for epilepsy: A review of approaches in the United States and Europe

M. Baulac, R. Porter, V. Nohria, 2010, Epilepsy Research.

Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability

M. Brodie, J. French, V. Nohria, 2014, Epilepsy Research.

The action of dazopride to enhance gastric emptying and block emesis

B. Costall, R. Naylor, S. Gunning, 1987, Neuropharmacology.

Comparison of the doubly labeled water (2H2(18)O) method with indirect calorimetry and a nutrient-balance study for simultaneous determination of energy expenditure, water intake, and metabolizable energy intake in preterm infants.

W. Coward, A. Lucas, V. Nohria, 1986, The American journal of clinical nutrition.

Behavioural actions of neuroleptics are not reduced by hypophysectomy

B. Costall, R. Naylor, V. Nohria, 1982, The Journal of pharmacy and pharmacology.

Retigabine – A Promising New Antiepileptic Drug with a Novel Mechanism of Action

M. Brodie, V. Nohria, 2007 .